Chikungunya
ARFANIL



Chikungunya (in the Makonde language "that leans downward") virus (CHIKV) is an insect-borne virus, of the genus Alphavirus, that is transmitted to humans by virus-carrying Aedes mosquitoes. CHIKV manifests itself with an acute febrile phase of the illness lasting only two to five days, followed by a prolonged arthralgic disease that affects the joints of the extremities. The pain associated with CHIKV infection of the joints persists for weeks or months, or in some cases years. There are no specific treatments for Chikungunya. There is no vaccine currently available. A University of Malaya study found that for arthritis-like symptoms that are not relieved by aspirin and non-steroidal anti-inflammatory drugs (NSAID). Unpublished studies in cell culture and monkeys show no effect of chloroquine treatment on reduction of chikungunya disease. (Ref: Chikungunya - Wikipedia, The free encyclopedia, Oct 2010)

All patients suffered with arthritis. The most frequently affected joints were fingers, wrists, toes, and ankles. Patients remained symptomatic after the tenth day with chronic peripheral rheumatism, characterized by severe joint pain and multiple tenosynovitis. Follow-up demonstrated slow improvement in joint pain and stiffness despite symptomatic treatment, mainly anti-inflammatory and analgesic drugs. In the current series we describe 2 stages of the disease, an initial severe febrile and eruptive polyarthritis, followed by disabling peripheral rheumatism that can persist for months.
(Ref: Simon F, et al, Medicine (Baltimore). 2007 May; 86(3): 123-37.)

There are no specific drugs to cure the disease. Treatment is directed primarily at relieving the symptoms, including the joint pain. There is no commercial Chikungunya vaccine. Ref: Chikungunya fever archive, WHO Media center (Oct 10)

For Joint pain in Chikungunya
Prescribe ARFANIL ® Capsules
A very effective formulation in Rheumatoid Arthrits.

Efficacy of an Ayurvedic formulation in Rheumatoid Arthritis, A double blind Placebo controlled, crossover study, Kulkarni RR, et al, Indian Journal of Pharmacology 1992; 24; 98-101

Safety: Safe dose in a man of 70 kg is 117.53 gm per day
Dose: 1 TDS Availability: 21/60 Caps in Plastic bottle

For composition, toxicity report and clinical trial reports of ARFANIL ®, please refer to our product details for 'Rheumatoid Arthritis' on this site.

Important observation: RA+ve and RA-ve, both patients show excellent results.
A leading Orthopedic (Pune): Excellent Results in 35 patients only with Arfanil Capsules.